Results 221 to 230 of about 21,386 (303)

Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCD. [PDF]

Blood Adv
Zhang L, Liu QH, Zhou H, Zhang HL, Dong YJ, Wang XB, Wang LQ, Su LP, Yan XJ, Li Y, Zhang MZ, Ding KY, Wang HH, Peng HL, Zhong LY, Yang L, Bi LT, Gao D, Gao GX, Huang L, Sun CY, Song J, Qian WB, Huang WR, Li ZL, Liu Y, Li J.   +26 more
europepmc   +1 more source

Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab

CEN Case Reports, 2020
Norihiro Furutera, N. Fukunaga, J. Okita, Tomoko Suzuki, Yuko Suenaga, Yuzo Oyama, Kohei Aoki, A. Fukuda, Takeshi Nakata, N. Uesugi, T. Daa, S. Hisano, H. Shibata   +12 more
semanticscholar   +1 more source

Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis. [PDF]

Eur J Haematol
Blommers M, Selegean S, Wood RK, Sarmiento Bustamante M, Shyamsundar S, Wiley EA, Comeau E, Shawwa AA, Rose-John S, Fajgenbaum DC, Chen LYC.   +10 more
europepmc   +1 more source

A Placebo-Controlled Exploratory Trial of Sirolimus for Tocilizumab-Resistant Idiopathic Multicentric Castleman Disease: Early Termination and Long-Term Extension Results Based on Descriptive Results From Two Patients. [PDF]

Cureus
Koga T, Sumiyoshi R, Shimizu T, Hosogaya N, Fukushima C, Yamamoto H, Yoshifuji H, Higa S, Kawakami A.   +8 more
europepmc   +1 more source

A Phase Ib Investigator-Initiated Trial of Filgotinib in Patients With Idiopathic Multicentric Castleman Disease. [PDF]

Cureus
Fukui S, Sumiyoshi R, Koga T, Hosogaya N, Narita S, Morimoto S, Yano H, Katsube A, Yano S, Masaki Y, Tsunoda S, Sato S, Migita K, Matsuyama K, Kato N, Kawamoto A, Kawakami A.   +16 more
europepmc   +1 more source

IgG4-positive cell infiltration in various cardiovascular disorders - results from histopathological analysis of surgical samples [PDF]

, 2017
Hideki Ozawa, Koichi Sohmiya, Masaaki Hoshiga, Masahiro Daimon, Nobukazu Ishizaka, Ryoto Hourai, Satomi Kasashima, Shu-ichi Fujita, Takahiro Katsumata, Yasuhiro Ogino, Yohei Yamauchi, Yoshinobu Hirose   +11 more
core   +1 more source

Idiopathic Multicentric Castleman Disease: Still a Diagnostic Conundrum?

Frits van Rhee
openalex   +1 more source

Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model. [PDF]

Ann Hematol
Karatisidis L, Mprotsis T, Intzes S, Zagoridis K, Vrachiolias G, Karatisidou V, Bezirgianidou Z, Liapis K, Kotsianidis I, Spanoudakis E.   +9 more
europepmc   +1 more source

Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience. [PDF]

J Hematol
Jitaru C, Symeonidis A, Badelita S, Katodritou E, Colita A, Mpanti A, Bancos A, Tigu B, Rotariu P, Urian L, Rus I, Dima D, Bojan A, Damian M, Labropoulou V, Muresan MS, Fotiou D, Fetica B, Petrushev B, Dascalescu A, Dalampira D, Buruiana S, Constantinescu C, Zdrenghea M, Dimopoulos MA, Tomuleasa C, Terpos E.   +26 more
europepmc   +1 more source

Clinicopathological characteristics of unicentric retroperitoneal Castleman’s disease: a study of 14 cases [PDF]

core   +1 more source